Tongqing Zhou

Dr. Tongqing Zhou

orcid

Biography

Dr. Tongqing Zhou is an NIH Earl Stadtman Investigator and Chief of the Structural Virology and Vaccinology Section at the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, NIH. His research focuses on the application of cryo-electron microscopy (cryo-EM) and X-ray crystallography to elucidate the structural basis of broadly neutralizing antibodies (bNAbs) against viral pathogens, particularly those that use type I fusion mechanisms, including HIV-1, Influenza, RSV, HPIV, HMPV, SARS-CoV-2, and HTLV. His laboratory also employs bioinformatics to investigate antibody ontogeny, guiding the development of bNAbs. A third major area of research in his lab is structure- and AI-based vaccine design as well as the testing of novel immunogens. Dr. Zhou has authored more than 180 peer-reviewed publications, with approximately 30 appearing in Nature, Science, and Cell. He has been recognized as a Highly Cited Researcher in Microbiology by Clarivate Analytics (formerly Thomson Reuters) for the past ten consecutive years. He is a co-inventor on numerous patents related to vaccine candidates and therapeutic antibodies for HIV, RSV, and HPIV, including contributions to the FDA-approved RSV vaccine Arexvy. Dr. Zhou earned his B.S. in Biochemistry from Wuhan University in 1989 and his Ph.D. in Cell Biology from the Chinese Academy of Sciences in 1994. Prior to joining the VRC in September 2001, he completed postdoctoral training in X-ray crystallography at

Affiliations

No affiliation has been shared yet.

Honors and Awards

No honors or awards have been shared yet.

Experience

No experience has been shared yet.